Passage Bio reports positive Phase 1/2 trial results for PBFT02 in frontotemporal dementia, with planned protocol amendments for safety optimization. Passage Bio, Inc. announced positive results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback